Summer Stack Research Peptides | Veyvora

By the end of this page, you will know exactly what the Summer Stack bundle contains, what the batch documentation must show before any in-vitro use, and where to confirm current pricing and availability on the live Veyvora en-GB listing.

Check current price and availability in the live offer block below before placing an order, no GBP figure is reproduced here, as unverified prices are not published on this page.

Veyvora’s Summer Stack is a paired research-pen bundle containing a Melanotan II 20 pen and a Retatrutide 20 pen, supplied strictly for in-vitro laboratory research use only (Veyvora, 2026). It pairs pigmentation research with entry-level metabolic support and carries a stated 12% saving against the individual pen prices. Both pens are labelled as research reagents; neither is a licensed medicine, and neither is authorised for human administration under UK law [2].

Field	Detail
Bundle name	Summer Stack peptides
Component 1	Melanotan II 20 pen (melanocortin pigmentation research format)
Component 2	Retatrutide 20 pen (triple-agonist metabolic research format)
Stated saving	12% versus individual pen prices
Storage	2–8 °C (cold-chain dispatched)
Dispatch	24-hour dispatch stated by Veyvora (2026)
Use classification	Laboratory research use only
Price	See the live product page

Veyvora states that each pen is independently assayed, with a certificate of analysis (CoA) linked to the batch number and reporting identity and HPLC purity of at least 98.0% (Veyvora, 2026). That documentation is the primary trust signal for researchers assessing identity and purity, not the stack marketing name.

Page last reviewed: 2026. Prices and regulatory status must be confirmed against the live Veyvora en-GB listing and current MHRA guidance at the time of purchase.

---

Key Takeaways

• The Summer Stack pairs two analytically separate research reagents, Melanotan II 20 and Retatrutide 20, each requiring its own batch CoA before any in-vitro use.
• Fill volume, concentration and excipients must be confirmed from the lot label and batch CoA, not inferred from the pen name.
• Neither component is a UK-licensed medicine; both are restricted to in-vitro laboratory use by competent persons.
• The bundle carries a stated 12% saving; pricing, dispatch terms and cold-chain policy must be verified on the live Veyvora en-GB listing at the time of purchase.

---

Summer Stack Research Peptides: Exact Bundle Identity

The pen designations “Melanotan II 20” and “Retatrutide 20” are drawn from Veyvora’s catalogue positioning. Exact fill volume, peptide concentration, excipients and device specifications must be confirmed against the lot label and the batch CoA for that specific unit. Inferring those values from the pen name alone misrepresents the specification. To understand what the purity figure on that certificate can and cannot establish, see how HPLC purity should be interpreted.

Confirm current price and availability in the live offer block before placing an order, no GBP figure is reproduced here, as unverified prices are not published on this page.

Field	Detail
Bundle name	Summer Stack peptides
Component 1	Melanotan II 20 pen (melanocortin pigmentation research format)
Component 2	Retatrutide 20 pen (triple-agonist metabolic research format)
Fill volume	3 mL
Peptide concentration	6.67 mg/mL per pen (20 mg ÷ 3 mL)
Storage	2–8 °C (cold-chain dispatched)
Use classification	Laboratory research use only
Price	See the live product page

Included Components

The Summer Stack contains two research pens, Melanotan II 20 and Retatrutide 20, each supplied as a pre-filled 3 mL / 300-click research pen for in-vitro laboratory use only (Veyvora, 2026). Chemically, Melanotan II is a cyclic heptapeptide analogue of α-melanocyte-stimulating hormone (α-MSH), assigned CAS number 121062-08-6. Retatrutide (development code LY3437943) is a single synthetic peptide that acts as an agonist at three receptors, the GIP, GLP-1 and glucagon receptors. Those chemical identities describe the named substances in the published literature and in PubChem; they do not confirm that a given pen contains either substance at a stated strength or purity, which is why the batch CoA for that specific lot is the required confirmation document [1].

Field	Melanotan II 20 Pen	Retatrutide 20 Pen
Chemical identity	Cyclic α-MSH analogue; CAS 121062-08-6	Triple GIP/GLP-1/glucagon agonist; LY3437943
Pen designation	Melanotan II 20	Retatrutide 20
Fill volume	3 mL	3 mL
Peptide concentration	6.67 mg/mL (20 mg ÷ 3 mL)	6.67 mg/mL (20 mg ÷ 3 mL)
Excipients / solvent	See batch COA	See batch COA
Storage	2–8 °C	2–8 °C
Use classification	In-vitro laboratory research only	In-vitro laboratory research only
Individual product page	Confirm from live en-GB listing	Confirm from live en-GB listing

Researchers who want the mechanistic background on the metabolic component can consult the retatrutide versus tirzepatide comparison for context on the triple-agonist receptor profile.

Bundle-level Evidence Boundary

Published chemical records for Melanotan II and Retatrutide establish the identity and in-vitro behaviour of each substance individually; they do not establish what a combined pen stack produces in any biological system. Treat the two components as analytically separate: a CoA for the Melanotan II 20 pen covers that lot alone, and a CoA for the Retatrutide 20 pen covers its lot alone. Neither document, nor both together, constitutes evidence of a combined or additive effect. The two pens are paired here as a procurement convenience covering pigmentation and entry-level metabolic research; each also carries its own separate evidence base and COA.

Supplier catalogue positioning is authoritative only for Veyvora’s own stated specification and commercial terms. It is not independent evidence of purity, identity or any biological outcome, and it does not substitute for method-validated batch documentation assessed under ICH Q2(R2) criteria, covering specificity, accuracy, precision and range [1]. Where a CoA is absent or does not name the analytical method and the testing laboratory, treat the contents as labelled claims only, not confirmed composition.

Batch Documents: What a Valid CoA Must Show

A valid batch CoA for each pen in the Summer Stack must carry the lot number printed on that pen’s label, name the analytical method used (such as HPLC or mass spectrometry), and state appearance, identity and purity results for that specific lot, not for the product class in general. Veyvora states that each batch is independently assayed by Asterion and its internal laboratory using HPLC, mass spectrometry and endotoxin assay, with a CoA linked to the batch number and an HPLC purity of at least 98.0% (Veyvora, 2026); confirm that claim against the certificate supplied with your consignment before use. Where a testing laboratory asserts United Kingdom Accreditation Service (UKAS) accreditation, that status must appear on the certificate itself rather than being assumed from the supplier’s catalogue description alone.

To verify a batch against its CoA, match the lot string on the pen label character-for-character with the string on the certificate before recording any analytical result.

Handling and Storage

Cold-chain integrity is consignment-specific. Veyvora states that research-peptide orders are dispatched under documented cold-chain conditions in an insulated bag with a gel ice pack (Veyvora, 2026); inspect the condition of each delivery on arrival before accepting it.

Handling both pens is a Control of Substances Hazardous to Health (COSHH) matter under United Kingdom laboratory regulations [2]. Appropriate containment, personal protective equipment (PPE), spill procedures and waste disposal all apply. For post-delivery storage conditions and stability data relevant to each component, consult research-peptide storage and stability guidance.

Commercial Terms

Price, availability, VAT treatment, dispatch cut-offs, courier selection, cold-pack policy, territory restrictions and returns for the Veyvora Summer Stack are subject to the merchant’s live United Kingdom listing. The stated 12% bundle saving is confirmed on the Veyvora category page, but the resulting GBP figure is not verified here and must be confirmed directly on the Veyvora research peptides catalogue before any purchasing decision. Do not rely on aggregator pages, cached prices or non-UK locale listings as price evidence.

Veyvora states that research-peptide orders are dispatched within 24 hours under documented cold-chain conditions in an insulated bag with a gel ice pack (Veyvora, 2026); the cold-pack and dispatch terms applicable to a specific order must be confirmed against the current en-GB checkout policy at the time of purchase. Related aesthetics and metabolic formats can be compared across the Veyvora research peptides catalogue for side-by-side assessment.

Research-Use-Only Limitations

Neither Melanotan II nor Retatrutide is a UK-licensed medicine for any human indication, including pigmentation, tanning or metabolic outcomes. Under the Human Medicines Regulations 2012, a product presented for treating or preventing disease in humans, or for administration to humans for a medicinal purpose, qualifies as a medicinal product and generally requires a marketing authorisation [2]. The MHRA’s published guidance confirms that classification as a medicine follows the product’s presentation and intended purpose, not its labelling as a research reagent [3].

That is why the Summer Stack’s Melanotan II 20 and Retatrutide 20 pens are restricted to in-vitro laboratory work by competent persons; that positioning does not authorise human administration, clinic protocols or any cosmetic or metabolic outcome claim.

To understand what an HPLC purity figure can and cannot establish for a given protocol, consult Veyvora’s guide on how HPLC purity should be interpreted, then verify a batch against its CoA using the lot number on the pen before committing to any in-vitro study design.

Ready to proceed? View the Summer Stack on the Veyvora en-GB catalogue to confirm current price, availability and batch documentation before ordering.

Sources

[1] ICH Official web site : ICH, ich.org, https://www.ich.org/page/quality-guidelines [2] legislation.gov.uk, https://www.legislation.gov.uk/uksi/2012/1916/contents [3] European Medicines Agency (EMA), gov.uk, 2023, https://www.gov.uk/guidance/decide-if-your-product-is-a-medicine-or-a-medical-device